Journal Article

The Splice Index as a prognostic biomarker of strength and function in myotonic dystrophy type 1

Hartman, Julia M., Dekdebrun, Jeanne, Gaynor, Alison, Lapato, Dana M., Kiefer, Michael, Berggren, Kiera N., Ikegami, Kobe, Hale, Melissa A., Thornton, Charles A., Provenzano, Marina, Bates, Kameron, Butler, Amanda, Hung, Man, Jones, Aileen, Johnson, Nicholas E.

2025

Overview

BACKGROUNDMyotonic dystrophy type 1 (DM1) is a multisystemic, CTG repeat expansion disorder characterized by a slow, progressive decline in skeletal muscle function. A biomarker correlating RNA mis-splicing, the core pathogenic disease mechanism, and muscle performance is crucial for assessing response to disease-modifying interventions. We evaluated the Myotonic Dystrophy Splice Index (SI), a composite RNA splicing biomarker incorporating 22 disease-specific events, as a potential biomarker of DM1 muscle weakness.METHODSTotal RNA sequencing of tibialis anterior biopsies from 58 DM1 participants and 33 unaffected/disease controls was used to evaluate RNA splicing events across the disease spectrum. Targeted RNA sequencing was used to derive the SI from biopsies collected at baseline (n = 52) or a 3-month (n = 37) follow-up visit along with clinical measures of muscle performance.RESULTSThe SI demonstrated significant associations with measures of muscle strength and ambulation, including ankle dorsiflexion (ADF) strength and 10-meter run/fast walk (Pearson's r = -0.719 and -0.680, respectively). The SI was relatively stable over 3 months (intraclass correlation coefficient [ICC] = 0.863). Latent-class analysis identified 3 DM1 subgroups stratified by baseline SI (SIMild, SIModerate, and SISevere); SIModerate individuals had a significant increase in the SI over 3 months. Multiple linear regression modeling revealed that baseline ADF and SI were predictive of strength at 3 months (adjusted R² = 0.830).CONCLUSIONThe SI is a reliable biomarker that captures associations of RNA mis-splicing with physical strength and mobility and has prognostic utility to predict future function, establishing it as a potential biomarker for assessment of therapeutic target engagement.TRIAL REGISTRATIONClinicalTrials.gov NCT03981575.FUNDINGFDA (7R01FD006071), Myotonic Dystrophy Foundation, Wyck Foundation, Muscular Dystrophy Association, Novartis, Dyne, Avidity, PepGen, Takeda, Sanofi Genzyme, Pfizer, Arthex, and Vertex Pharmaceuticals.

• Publisher: American Society for Clinical Investigation
• Subject: Adult / Analysis / Ankle / Avidity / Biological markers / Biomarkers / Biomarkers - metabolism / Biopsy / Clinical Research and Public Health / Datasets / Diagnosis / Female / Humans / Male / Middle Aged / Muscle biology / Muscle Strength / Muscle, Skeletal - metabolism / Muscle, Skeletal - pathology / Muscle, Skeletal - physiopathology / Muscular dystrophy / Musculoskeletal system / Myotonic dystrophy / Myotonic Dystrophy - diagnosis / Myotonic Dystrophy - genetics / Myotonic Dystrophy - metabolism / Myotonic Dystrophy - pathology / Myotonic Dystrophy - physiopathology / Prognosis / Ribonucleic acid / RNA / RNA Splicing / Skeletal muscle / Splicing / Therapeutic targets